NASDAQ:ARAY - Accuray Stock Price, Forecast & News

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray Incorporated (NASDAQ:ARAY) announced its earnings results on Tuesday, January, 28th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.19. The medical equipment provider had revenue of $98.83 million for the quarter, compared to analysts' expectations of $98.45 million. Accuray had a negative return on equity of 23.59% and a negative net margin of 0.30%. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. View Accuray's Earnings History.

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Accuray.

Accuray updated its FY 2020 After-Hours earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $412.77 million.

2 brokerages have issued 1-year target prices for Accuray's stock. Their forecasts range from $4.00 to $9.50. On average, they expect Accuray's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 103.3% from the stock's current price. View Analyst Price Targets for Accuray.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Accuray.

Headlines about ARAY stock have been trending positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Accuray earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Accuray.

Some companies that are related to Accuray include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Intel (INTC), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Tesla (TSLA), Abeona Therapeutics (ABEO) and Aduro BioTech (ADRO).

Accuray's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.45%), Archon Capital Management LLC (4.82%), Heartland Advisors Inc. (3.88%), Russell Investments Group Ltd. (3.87%), Royce & Associates LP (2.31%) and State Street Corp (1.80%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.

ARAY stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Mackay Shields LLC, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Oxford Asset Management LLP, State Street Corp, Bank of New York Mellon Corp and Algert Global LLC. Company insiders that have sold Accuray company stock in the last year include Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Patrick Spine and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.

ARAY stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Assenagon Asset Management S.A., Lapides Asset Management LLC, Royce & Associates LP, Barrow Hanley Mewhinney & Strauss LLC, California Public Employees Retirement System, Archon Capital Management LLC and Boston Partners. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters and Joshua Levine. View Insider Buying and Selling for Accuray.

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARAY stock can currently be purchased for approximately $3.32.

Accuray has a market capitalization of $300.36 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.

The official website for Accuray is http://www.accuray.com/.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at investors.accuray.com.